Late-breaking data from protected tavr trial demonstrate reduced risk of disabling stroke, low complication rate with sentinel™ cerebral protection system

Results from largest randomized tavr trial to date presented at tct 2022 marlborough, mass. , sept. 17, 2022 /prnewswire/ -- boston scientific corporation (nyse:bsx) has announced results from the protected tavr clinical trial evaluating the sentinel™ cerebral protection system, which is designed to capture and remove embolic debris stemming from transcatheter aortic valve replacement (tavr) before it can reach the brain and potentially cause a stroke.
BSX Ratings Summary
BSX Quant Ranking